- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07510165
Effets du Rétinaldéhyde Stabilisé sur la Peau Âgée : Étude en Face Divisée
Évaluation multimodale des changements structurels et spectraux de la peau liés au vieillissement induits par l'application topique de rétinaldéhyde stabilisé à 0,1 % et 0,05 % : une étude en face divisée de 24 semaines
The goal of this clinical trial is to learn if retinaldehyde cream improves the appearance of aging skin in women aged 30 to 60 years. Retinaldehyde is a form of vitamin A that the skin can convert into retinoic acid, which is known to help with skin aging. The study tested two strengths of retinaldehyde cream: a stronger version with 0.1% retinaldehyde and a weaker version with 0.05% retinaldehyde.
The main questions the study aimed to answer were: whether retinaldehyde cream improves skin hydration and reduces oiliness, whether it improves skin firmness and elasticity, whether it reduces wrinkles and improves skin texture, whether it reduces uneven skin tone and pigmentation, and whether the stronger 0.1% cream works better than the weaker 0.05% cream.
Researchers compared the two cream strengths by applying them to opposite sides of the same face. The stronger 0.1% cream was applied to the left side and the weaker 0.05% cream was applied to the right side. This approach allowed researchers to compare the two strengths directly in the same person under the same conditions.
56 women with visible signs of aging skin took part in the study at the Medical University of Silesia in Poland. One participant left the study early due to skin irritation. The remaining 55 women completed all 24 weeks of the study.
Participants apply the creams in the evening, starting with twice a week for the first 2 weeks, then increasing to 3 times a week in week 3 and 4 times a week in week 4, based on skin tolerance, for 24 weeks total. They also used a provided skincare routine every day, which included a lipid face cream, a cleansing lotion, and a sunscreen with SPF 50 to protect their skin during the study.
Participants were assessed 3 times: before starting the creams, after 12 weeks of use, and after 24 weeks of use. At each visit, researchers measured skin hydration, oiliness, elasticity, firmness, wrinkle depth, skin density, skin color, and other skin properties using a range of specialized skin measurement tools. Neither the participants nor the researchers assessing outcomes knew which cream strength was applied to which side of the face.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This study investigated the effects of topically applied stabilized retinaldehyde (RAL) at two concentrations (0.1% and 0.05%) on aging skin in 56 women (55 completing the study) aged 30-60 years (mean age 44.25 ± 8.1 years) with visible signs of photoaging including fine lines, wrinkles, pigmentation disorders, seborrhea, and loss of skin firmness.
A 24-week, double-blind, split-face design was employed. The 0.1% RAL formulation was applied to the left side of the face and the 0.05% formulation to the right side. Application frequency started with twice weekly for the first 2 weeks, increasing to three times per week in week 3 and four times per week in week 4, based on skin tolerance. Both formulations contained stabilized retinaldehyde encapsulated in a cyclodextrin-glycosaminoglycan complex to enhance stability and provide controlled transdermal delivery. The tested products were commercially available formulations provided by the study collaborator. All participants followed a standardized background skincare regimen consisting of a lipid cream, cleansing lotion, and SPF 50 sunscreen throughout the study period.
Skin assessments were performed at baseline (T0), after 12 weeks (T1), and after 24 weeks (T2) using a multimodal diagnostic approach at the Department of Basic Biomedical Sciences, Faculty of Pharmaceutical Sciences, Medical University of Silesia.
Biophysical measurements included stratum corneum hydration (Corneometer CM 825), sebum excretion rate (Sebumeter SM 815), and melanin and erythema indices (Mexameter MX 18). Structural assessments were performed using high-frequency ultrasound (DUB SkinScanner, 50 MHz) to evaluate skin density and epidermal thickness, and the Cutometer MPA 580 to assess skin viscoelasticity and elasticity parameters (R2, R5, R7, Q1, Q2). Wrinkle depth and surface parameters were evaluated using Antera 3D imaging. Optical and imaging assessments included colorimetric analysis of L*, a*, and b* values (Antera 3D), hyperspectral imaging across 400-1000 nm spectral range (SPECIM IQ), and Gray Level Co-Occurrence Matrix (GLCM) texture analysis including contrast and homogeneity of standardized clinical photographs (Fotomedicus system).
The study aimed to determine whether stabilized RAL induces measurable structural, vascular, spectral, and optical changes in aging skin, and to compare the dose-dependent efficacy of 0.1% versus 0.05% concentrations across all measured parameters.
One participant withdrew from the study due to facial erythema and discomfort. No other serious adverse events were reported.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Sosnowiec, Pologne, 41-205
- Department of Basic Biomedical Science, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Sosnowiec, Poland
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age 30-60 years
- Presence of wrinkles, dark spots, acne, seborrhea
- Decreased skin firmness
Exclusion Criteria:
- Exacerbated active atopic dermatitis on the face
- Pregnancy
- Skin infections
- Numerous erosions or excoriations on facial skin
- No aesthetic medical treatments within the preceding 6 months
- Administration of botulinum toxin within the preceding 3 months
- Irritated, dry skin
- Irritated or excessively dry skin
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Retinaldehyde 0.1% (Left Side)
Stabilized retinaldehyde 0.1% formulation applied to the left side of the face for 24 weeks. Application frequency started with twice weekly for the first 2 weeks, increasing to three times per week in week 3 and four times per week in week 4, based on skin tolerance. |
Stabilized retinaldehyde 0.1% encapsulated in a cyclodextrin-glycosaminoglycan complex, formulated as a topical cosmetic cream, applied to the left side of the face. Application frequency started with twice weekly for the first 2 weeks, increasing to three times per week in week 3 and four times per week in week 4, based on skin tolerance, for a total of 24 weeks.
Autres noms:
|
|
Expérimental: Retinaldehyde 0.05% (Right Side)
Stabilized retinaldehyde 0.05% formulation applied to the right side of the face for 24 weeks. Application frequency started with twice weekly for the first 2 weeks, increasing to three times per week in week 3 and four times per week in week 4, based on skin tolerance. |
Stabilized retinaldehyde 0.05% encapsulated in a cyclodextrin-glycosaminoglycan complex, formulated as a topical cosmetic cream, applied to the right side of the face. Application frequency started with twice weekly for the first 2 weeks, increasing to three times per week in week 3 and four times per week in week 4, based on skin tolerance, for a total of 24 weeks.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Skin Hydration
Délai: Baseline and 24 weeks
|
Stratum corneum hydration measured using Corneometer CM 825 (Courage+Khazaka, Germany). Three consecutive measurements taken at predefined anatomical landmarks on both sides of the face. |
Baseline and 24 weeks
|
|
Sebum Excretion Rate
Délai: Baseline and 24 weeks
|
Sebum levels measured using Sebumeter SM 815 (Courage+Khazaka, Germany). Single measurement at each predefined anatomical site applied with constant pressure of 10 N for 30 seconds. |
Baseline and 24 weeks
|
|
Melanin Index
Délai: Baseline and 24 weeks
|
Melanin content measured using Mexameter MX 18 (Courage+Khazaka, Germany). Three consecutive measurements taken at predefined anatomical landmarks. |
Baseline and 24 weeks
|
|
Erythema Index
Délai: Baseline and 24 weeks
|
Erythema measured using Mexameter MX 18 (Courage+Khazaka, Germany). Three consecutive measurements taken at predefined anatomical landmarks. |
Baseline and 24 weeks
|
|
Skin Density and Epidermal Thickness
Délai: Baseline and 24 weeks
|
Assessed using high-frequency ultrasound DUB SkinScanner 50 MHz. Skin density measured using ROI function directly beneath epidermis. Epidermal thickness calculated in millimeters based on A-scan. |
Baseline and 24 weeks
|
|
Skin Viscoelasticity and Elasticity
Délai: Baseline and 24 weeks
|
Assessed using Cutometer MPA 580 (Courage+Khazaka, Germany) with 2 mm probe. Parameters R2, R5, R7, Q1, Q2 extracted from deformation curves. |
Baseline and 24 weeks
|
|
Wrinkle Depth and Surface Parameters
Délai: Baseline and 24 weeks
|
Assessed using Antera 3D imaging system (Miravex Limited, Ireland) with multi-directional illumination. ROIs of 20x20 mm at predefined anatomical landmarks. |
Baseline and 24 weeks
|
|
Colorimetric Parameters
Délai: Baseline and 24 weeks
|
L*, a*, b* values measured using Antera 3D imaging system (Miravex Limited, Ireland). Data extracted from standardized ROIs of 20x20 mm. |
Baseline and 24 weeks
|
|
Skin Texture - GLCM Analysis
Délai: Baseline and 24 weeks
|
Contrast and homogeneity assessed using Gray Level Co-Occurrence Matrix (GLCM) analysis of standardized clinical photographs taken with Fotomedicus system (Elfo, Poland). ROIs of 200x200 pixels extracted from central cheek coordinates. |
Baseline and 24 weeks
|
|
Hyperspectral Imaging
Délai: Baseline and 24 weeks
|
Reflectance and hemoglobin variability assessed using SPECIM IQ hyperspectral camera (Specim, Finland), spectral range 400-1000 nm, spectral resolution 5 nm. ROIs of 100x100 pixels from predefined cheek coordinates. |
Baseline and 24 weeks
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Sławomir Wilczyński, Prof. PhD, Department of Basic Biomedical Science, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Sosnowiec, Poland
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- PCN/CBN/0022/KB1/27
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
De-identified individual participant data underlying the results reported in publications will be shared upon reasonable request. This includes data necessary to reproduce the findings presented in the articles. Data will be available after publication, subject to institutional policies, ethical approval, and applicable data protection regulations. No directly identifiable data will be shared. Supporting documents such as the study protocol and statistical analysis plan may also be made available upon request.
Délai de partage IPD
Data will be available beginning 3 months after publication of the final study results and will remain available for 5 years.
Critères d'accès au partage IPD
Access to de-identified individual participant data will be provided to qualified researchers upon reasonable request. Requests should include a brief description of the research purpose. Requests will be reviewed by the study investigators. Data will be shared in accordance with institutional policies, ethical considerations, and applicable data protection regulations.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .